Biotech IPO

Latest Headlines

Latest Headlines

MyoKardia plots an $86M IPO with a novel take on cardio R&D

MyoKardia, taking a rare disease approach to cardiovascular drug development, is plotting to go public in an $86 million IPO and raise cash to push its Sanofi-partnered pipeline.

Roche-partnered Oryzon plans Madrid IPO as launchpad to Nasdaq

Oryzon Genomics has joined the wave of European biotechs to file for an IPO on their home continent. But the Roche-partnered epigenetics specialist is doing things differently, first by going public in the biotech backwater of the Madrid stock exchange and then by using this listing as a launchpad for a Nasdaq IPO.

Acacia looks to a $230M IPO in London as it steers through PhIII

Last fall, Acacia Pharma's virtual crew cheered the late-stage success of a drug designed to prevent postoperative nausea and vomiting by bringing in strategic advisers to help hammer out a path forward. And evidently, they concluded that setting out to raise $230 million on the London Stock Exchange was the right way to go.

Mirna moves into unchartered waters with $81M IPO filing

Mirna Therapeutics is about to find out whether turbulence in the financial markets has blown the IPO window shut. The company brushed off concerns that the three-year IPO party is winding down by filing to raise up to $80.5 million to advance its tumor suppressor into Phase II.

Gene therapy stalwart ReGenX plots a $100M IPO to strike out on its own

After years of outlicensing its gene therapy technology, ReGenX Bio is pressing forward with treatments of its own, filing to raise $100 million in an IPO to fund in-house R&D.

Adynxx eyes an IPO, late-stage program after pain drug clears a PhII hurdle

Adynxx says that their second shot at statistically significant results in a midstage study for their lead pain drug proved the charm. The San Francisco-based biotech didn't post any data, but CEO Rick Orr said that the drug hit the primary endpoint without raising any red flags on the safety side.

Erytech pushes ahead with plan to file IPO on Nasdaq to fund cancer pipeline

Erytech is poised to become the latest in a long line of European biotechs to head to Wall Street in search of cash. The proposal marks an escalation of the cancer biotech's long-running flirtation with U.S. investors, which has already seen it set up on the OTC market and tap stateside sources for its previous fundraising round.

UPDATED: Torrid pace of VC investing in H1 sets a new biotech record

The venture money machine backing the biotech industry in the U.S. was operating in overdrive during the second quarter, generating a record amount of investing in new drug development as IPOs continue their romp in the third year of a wide-open market.

Celgene backing Soon-Shiong's cancer biotech IPO, now dubbed NantKwest

Now that billionaire entrepreneur Patrick Soon-Shiong has taken control of tiny ConkWest and steered it toward a $173 million IPO, he's adding a makeover to the name that will fit more easily under the fast-growing NantWorks umbrella he's created.

Aimmune joins the biotech IPO scrum in search of $115M

Working off of an $80 million crossover round with newly won boasting rights to the FDA's breakthrough therapy designation in hand, Brisbane, CA-based Aimmune Therapeutics is wasting no time in diving into the heated IPO waters for biotech. The biotech filed plans to raise $115 million on Nasdaq, the latest in a scrum of developers anxious to tap into the long-running boom market.